[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-retatrutide-triumph-2-3-results-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":361,"_id":362,"_source":363,"_file":364,"_stem":365,"_extension":366},"\u002Fblog\u002Fzh\u002Fretatrutide-triumph-2-3-results","zh",false,"","Retatrutide TRIUMPH-2 与 TRIUMPH-3：糖尿病与心脏病人群的三期数据","本文属于一般性科普，不是医疗建议，也不是鼓励你去获取或使用任何东西。Retatrutide 仍处于试验阶段，尚未获批。下面这些数字，是一家公司从自己的试验里报出来的结果，既不是对任何疗效的承诺，也不是用药指导。","研究","tabler:chart-line","#4C9F70","2026-07-23","2026年7月","6 min","myPeptides Team","\u002Fassets\u002Freta_triumph_hero.png",{"type":19,"children":20,"toc":351},"root",[21,28,33,40,45,112,117,122,131,137,142,186,191,196,201,206,211,233,239,276,281,286,291,304,309],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31],{"type":27,"value":32},"一句话版本：2026 年 7 月 23 日，礼来公布了旗下三重激动剂 Retatrutide 另外两项三期试验的顶线结果。TRIUMPH-2 面向 2 型糖尿病成年人，TRIUMPH-3 面向重度肥胖合并已确诊心血管疾病的成年人。两项都达到了各自的减重目标，糖尿病那项里血糖控制也一并改善了。数据很硬。而要泼的这盆冷水，和 TRIUMPH-1 时一模一样：这只是公司的一份新闻稿，不是经过完整同行评审的数据集；Retatrutide 至今仍未获批；今天任何打着这个名号卖的东西，都是未获批的灰色市场货。",{"type":22,"tag":34,"props":35,"children":37},"h2",{"id":36},"triumph-22-型糖尿病人群的数字",[38],{"type":27,"value":39},"TRIUMPH-2：2 型糖尿病人群的数字",{"type":22,"tag":23,"props":41,"children":42},{},[43],{"type":27,"value":44},"TRIUMPH-2 招募了 1,152 名成年人，他们除了肥胖或超重，还患有 2 型糖尿病；试验在 80 周里测试了这款每周一次注射剂的三种剂量。",{"type":22,"tag":46,"props":47,"children":48},"table",{},[49,68],{"type":22,"tag":50,"props":51,"children":52},"thead",{},[53],{"type":22,"tag":54,"props":55,"children":56},"tr",{},[57,63],{"type":22,"tag":58,"props":59,"children":60},"th",{},[61],{"type":27,"value":62},"每周剂量",{"type":22,"tag":58,"props":64,"children":65},{},[66],{"type":27,"value":67},"80 周平均减重",{"type":22,"tag":69,"props":70,"children":71},"tbody",{},[72,86,99],{"type":22,"tag":54,"props":73,"children":74},{},[75,81],{"type":22,"tag":76,"props":77,"children":78},"td",{},[79],{"type":27,"value":80},"4 mg",{"type":22,"tag":76,"props":82,"children":83},{},[84],{"type":27,"value":85},"约 12.7%（约 13.5 公斤 \u002F 29.8 磅）",{"type":22,"tag":54,"props":87,"children":88},{},[89,94],{"type":22,"tag":76,"props":90,"children":91},{},[92],{"type":27,"value":93},"9 mg",{"type":22,"tag":76,"props":95,"children":96},{},[97],{"type":27,"value":98},"约 19.1%（约 20.6 公斤 \u002F 45.4 磅）",{"type":22,"tag":54,"props":100,"children":101},{},[102,107],{"type":22,"tag":76,"props":103,"children":104},{},[105],{"type":27,"value":106},"12 mg",{"type":22,"tag":76,"props":108,"children":109},{},[110],{"type":27,"value":111},"约 20.8%（约 22.5 公斤 \u002F 49.6 磅）",{"type":22,"tag":23,"props":113,"children":114},{},[115],{"type":27,"value":116},"除了减重，HbA1c——衡量三个月血糖控制的常用指标——平均最多降了 1.6 个百分点，安慰剂组只降了 0.2。对一款在糖尿病领域研发的药来说，同时管住体重和血糖，正是它的意义所在。",{"type":22,"tag":23,"props":118,"children":119},{},[120],{"type":27,"value":121},"Retatrutide 是一款三重激动剂：一个分子同时作用于 GIP、GLP-1 和胰高血糖素三种受体。正是胰高血糖素这第三个靶点，被认为让它比之前的 GLP-1 以及 GLP-1\u002FGIP 药物\"下手更狠\"。",{"type":22,"tag":23,"props":123,"children":124},{},[125],{"type":22,"tag":126,"props":127,"children":130},"img",{"alt":128,"src":129},"减重曲线一路向下，旁边是逐渐纤细的身形剪影","\u002Fassets\u002Freta_triumph_chart.png",[],{"type":22,"tag":34,"props":132,"children":134},{"id":133},"triumph-3更难啃的人群",[135],{"type":27,"value":136},"TRIUMPH-3：更难啃的人群",{"type":22,"tag":23,"props":138,"children":139},{},[140],{"type":27,"value":141},"TRIUMPH-3 挑的是一批更棘手的人：1,949 名重度肥胖并已确诊心血管疾病的成年人，无论是否合并 2 型糖尿病，都用两种较高剂量随访了 80 周。",{"type":22,"tag":46,"props":143,"children":144},{},[145,159],{"type":22,"tag":50,"props":146,"children":147},{},[148],{"type":22,"tag":54,"props":149,"children":150},{},[151,155],{"type":22,"tag":58,"props":152,"children":153},{},[154],{"type":27,"value":62},{"type":22,"tag":58,"props":156,"children":157},{},[158],{"type":27,"value":67},{"type":22,"tag":69,"props":160,"children":161},{},[162,174],{"type":22,"tag":54,"props":163,"children":164},{},[165,169],{"type":22,"tag":76,"props":166,"children":167},{},[168],{"type":27,"value":93},{"type":22,"tag":76,"props":170,"children":171},{},[172],{"type":27,"value":173},"约 21.6%",{"type":22,"tag":54,"props":175,"children":176},{},[177,181],{"type":22,"tag":76,"props":178,"children":179},{},[180],{"type":27,"value":106},{"type":22,"tag":76,"props":182,"children":183},{},[184],{"type":27,"value":185},"约 22.6%（约 25.3 公斤 \u002F 55.8 磅）",{"type":22,"tag":23,"props":187,"children":188},{},[189],{"type":27,"value":190},"礼来还报告这一组在心血管代谢指标上的改善——血压和甘油三酯都在其中——而对已经患有心脏病的人群来说，这恰恰是最有分量的那类数据。和这里的一切一样，在完整数据集出来之前，都请把它当作顶线数字看待。",{"type":22,"tag":34,"props":192,"children":194},{"id":193},"冷水还得泼",[195],{"type":27,"value":193},{"type":22,"tag":23,"props":197,"children":198},{},[199],{"type":27,"value":200},"有三件事给这份兴奋降降温，和第一项试验时说的是同样三件。",{"type":22,"tag":23,"props":202,"children":203},{},[204],{"type":27,"value":205},"它没获批。三期顶线数据是申报路上的一个里程碑，不是终点线。在监管机构审完整个材料包之前，不存在合法、凭处方开出的 Retatrutide——无论是用于糖尿病还是减重。",{"type":22,"tag":23,"props":207,"children":208},{},[209],{"type":27,"value":210},"\"顶线\"不等于完整数据集。新闻稿给你的，是挑得最好看的那几个数字。完整结果、安全性细节，以及那份永远最关键的脱落率与不良事件明细，都得等到后面——在某场医学大会上、在某本期刊里才会揭晓。",{"type":22,"tag":23,"props":212,"children":213},{},[214,216,223,225,231],{"type":27,"value":215},"而最实际的一点：眼下市面上流通的全是灰色市场货。正因为真正的药还没获批，网上打着\"retatrutide\"名号卖的，是不受监管的研究级原料，成分和纯度都成谜。试验里那些数字，是用一种成分明确的化合物、在临床环境下按剂量给药并全程监测得来的；它们完全说明不了论坛上某人卖的那支西林瓶到底是什么。这些我们在 ",{"type":22,"tag":217,"props":218,"children":220},"a",{"href":219},"\u002Fblog\u002Fretatrutide-triumph-1-results",[221],{"type":27,"value":222},"TRIUMPH-1 解读",{"type":27,"value":224},"和 ",{"type":22,"tag":217,"props":226,"children":228},{"href":227},"\u002Fblog\u002Fretatrutide-liver-damage-myths",[229],{"type":27,"value":230},"Retatrutide 肝损伤事实核查",{"type":27,"value":232},"里都聊得很透。",{"type":22,"tag":34,"props":234,"children":236},{"id":235},"你即将到处看到的剂量以及它们不是什么",[237],{"type":27,"value":238},"你即将到处看到的剂量，以及它们不是什么",{"type":22,"tag":23,"props":240,"children":241},{},[242,244,250,252,258,260,266,268,274],{"type":27,"value":243},"试验剂量——每周 4 mg、9 mg 和 12 mg——如今出现在每一篇报道里，而这也正是有人开始拿灰色市场西林瓶反推一张\"Retatrutide 剂量表\"的地方。这张表我们不会给你：上面那些剂量是礼来在临床监督下给的，不是拿来照抄的方案。工具能替你做的，只是中立的那一部分——算术。如果你已经知道一支西林瓶的浓度、又往里加了多少抑菌注射用水，我们的 ",{"type":22,"tag":217,"props":245,"children":247},{"href":246},"\u002Fcalculator",[248],{"type":27,"value":249},"Retatrutide 复溶计算器",{"type":27,"value":251},"会把目标剂量换算成注射器上确切的单位数；要是让你犯难的是配制这一步，",{"type":22,"tag":217,"props":253,"children":255},{"href":254},"\u002Fcalculator\u002Fbac-water",[256],{"type":27,"value":257},"该加多少抑菌注射用水",{"type":27,"value":259},"就专门做这一道计算。因为它是每周一次注射，药物在体内的水平会在两针之间起起落落——Retatrutide 半衰期的这条曲线，你可以在",{"type":22,"tag":217,"props":261,"children":263},{"href":262},"\u002Fplotter",[264],{"type":27,"value":265},"血药浓度曲线图",{"type":27,"value":267},"里看到。想了解已发表文献里报告的剂量，以及这款分子的基础知识，可以看我们的 ",{"type":22,"tag":217,"props":269,"children":271},{"href":270},"\u002Fglp1\u002Fretatrutide",[272],{"type":27,"value":273},"Retatrutide 资料页",{"type":27,"value":275},"。",{"type":22,"tag":34,"props":277,"children":279},{"id":278},"接下来会发生什么",[280],{"type":27,"value":278},{"type":22,"tag":23,"props":282,"children":283},{},[284],{"type":27,"value":285},"礼来表示，计划在 2027 年第一季度之前把 Retatrutide 递交给 FDA。正是这一步，才把一份顶线新闻稿变成一份可以审查的申请；而在监管机构真正看过完整的安全性与有效性材料之前，不存在获批、凭处方开出的 Retatrutide。TRIUMPH-2 和 TRIUMPH-3 的完整数据也会在医学大会和期刊上亮相，届时独立研究者就能核对新闻稿略过的那些细节。",{"type":22,"tag":34,"props":287,"children":289},{"id":288},"一句话总结",[290],{"type":27,"value":288},{"type":22,"tag":23,"props":292,"children":293},{},[294,296,302],{"type":27,"value":295},"又是两场三期胜利：2 型糖尿病人群最高减重 20.8%、HbA1c 下降 1.6 个百分点，已确诊心脏病人群最高达 22.6%。就现有进展看，Retatrutide 仍像是在研管线里最强的那款肠促胰素类药物。但它同样尚未获批，目前也只公布了顶线数据，今天更不可能通过受监管的渠道买到。读一份试验数据，和读一个卖货页面，完全是两码事。想从零开始搞懂这一类药，先从",{"type":22,"tag":217,"props":297,"children":299},{"href":298},"\u002Fwhat-are-peptides",[300],{"type":27,"value":301},"什么是肽",{"type":27,"value":303},"看起。",{"type":22,"tag":34,"props":305,"children":307},{"id":306},"参考来源",[308],{"type":27,"value":306},{"type":22,"tag":310,"props":311,"children":312},"ul",{},[313,327,339],{"type":22,"tag":314,"props":315,"children":316},"li",{},[317,319],{"type":27,"value":318},"礼来（投资者新闻稿），2026 年 7 月 23 日，",{"type":22,"tag":217,"props":320,"children":324},{"href":321,"rel":322},"https:\u002F\u002Finvestor.lilly.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-triple-agonist-retatrutide-successful-two-additional",[323],"nofollow",[325],{"type":27,"value":326},"Lilly's triple agonist retatrutide successful in two additional phase-3 obesity trials",{"type":22,"tag":314,"props":328,"children":329},{},[330,332],{"type":27,"value":331},"PharmExec，",{"type":22,"tag":217,"props":333,"children":336},{"href":334,"rel":335},"https:\u002F\u002Fwww.pharmexec.com\u002Fview\u002Fretatrutide-delivers-22-weight-loss-two-phase-iii-trials",[323],[337],{"type":27,"value":338},"Retatrutide delivers up to 22.6% weight loss in two new phase-III trials",{"type":22,"tag":314,"props":340,"children":341},{},[342,344],{"type":27,"value":343},"HCPLive，",{"type":22,"tag":217,"props":345,"children":348},{"href":346,"rel":347},"https:\u002F\u002Fwww.hcplive.com\u002Fview\u002Fretatrutide-meets-phase-3-weight-loss-endpoints-in-2-obesity-trials",[323],[349],{"type":27,"value":350},"Retatrutide meets phase-3 weight-loss endpoints in two obesity trials",{"title":7,"searchDepth":352,"depth":352,"links":353},2,[354,355,356,357,358,359,360],{"id":36,"depth":352,"text":39},{"id":133,"depth":352,"text":136},{"id":193,"depth":352,"text":193},{"id":235,"depth":352,"text":238},{"id":278,"depth":352,"text":278},{"id":288,"depth":352,"text":288},{"id":306,"depth":352,"text":306},"markdown","content:blog:zh:retatrutide-triumph-2-3-results.md","content","blog\u002Fzh\u002Fretatrutide-triumph-2-3-results.md","blog\u002Fzh\u002Fretatrutide-triumph-2-3-results","md"]